Patents by Inventor Gregory J. Carven

Gregory J. Carven has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20240016928
    Abstract: Disclosed herein are therapeutic use of isoform-specific, context-permissive inhibitors of TGF?1 in the treatment of disease that involve TGF?1 dysregulation.
    Type: Application
    Filed: August 1, 2023
    Publication date: January 18, 2024
    Inventors: Thomas Schurpf, Abhishek Datta, Gregory J. Carven, Constance Martin, Ashish Kalra, Kimberly Long, Alan Buckler
  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20230416405
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: March 13, 2023
    Publication date: December 28, 2023
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF
    Publication number: 20230348583
    Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.
    Type: Application
    Filed: March 31, 2023
    Publication date: November 2, 2023
    Inventors: Thomas SCHURPF, Gregory J. CARVEN, Abhishek DATTA, Kimberly LONG
  • ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
    Publication number: 20230190929
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Application
    Filed: July 21, 2022
    Publication date: June 22, 2023
    Inventors: Gregory J. CARVEN, Michelle STRAUB, Adriana DONOVAN, Katherine Jane TURNER
  • TGF?1-binding immunoglobulins and use thereof
    Patent number: 11643459
    Abstract: Disclosed herein are immunoglobulins, such as antibodies, and antigen binding portions thereof, that specifically bind complexes of GARP-TGF?1, LTBP1-TGF?1, LTBP3-TGF?1, and/or LRRC33-TGF?1. The application also provides methods of use of these immunoglobulins for, for example, inhibiting TGF?1 activity, and treating subjects suffering from TGF?1-related disorders, such as cancer and fibrosis.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: May 9, 2023
    Assignee: Scholar Rock, Inc.
    Inventors: Thomas Schurpf, Gregory J. Carven, Abhishek Datta, Kimberly Long
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 11634504
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 25, 2023
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Methods for using anti-myostatin antibodies
    Patent number: 11439704
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: September 13, 2022
    Assignee: Scholar Rock, Inc.
    Inventors: Gregory J. Carven, Michelle Straub, Adriana Donovan, Katherine Jane Turner
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20220064275
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: March 3, 2022
    Inventors: Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210340238
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: November 4, 2021
    Inventors: Abhishek Datta, Thomas Schurpf, Allan Capili, Stefan Wawersik, Christopher Chapron, Christopher Littlefield, Gregory J. Carven, Kevin B. Dagbay, Susan Lin, Justin W. Jackson, Caitlin Stein
  • Isoform-selective TGF?1 inhibitors and use thereof
    Patent number: 11130803
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 28, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • TGFBeta Antibodies, Methods and Uses
    Publication number: 20210277100
    Abstract: ProTGF?1-GARP complex-selective antibodies, polynucleotides capable of encoding the proTGF?1-GARP complex-selective antibodies or antigen-binding fragments, cells expressing proTGF?1-GARP complex-selective antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled proTGF?1-GARP complex-selective antibodies or antigen-binding fragments may be used to enhance an immune response in a subject, for example, against a cancer.
    Type: Application
    Filed: May 25, 2021
    Publication date: September 9, 2021
    Inventors: Gregory J. Carven, Thomas Schurpf, Katherine Turner
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210122814
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 29, 2021
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20210101998
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: November 24, 2020
    Publication date: April 8, 2021
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • ANTI-PRO/LATENT-MYOSTATIN ANTIBODIES AND USES THEREOF
    Publication number: 20210046180
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Application
    Filed: June 24, 2020
    Publication date: February 18, 2021
    Applicant: Scholar Rock, Inc.
    Inventors: Gregory J. CARVEN, Michelle STRAUB, Adriana DONOVAN, Katherine Jane TURNER
  • Tissue factor pathway inhibitor antibodies and uses thereof
    Patent number: 10875929
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: December 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Anti-pro/latent-Myostatin antibodies and uses thereof
    Patent number: 10751413
    Abstract: Aspects of the present disclosure relate to antibodies that specifically bind proMyostatin and/or latent Myostatin and uses thereof.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: August 25, 2020
    Assignee: Scholar Rock, Inc.
    Inventors: Gregory J. Carven, Michelle Straub, Adriana Donovan, Katherine Jane Turner
  • LTBP COMPLEX-SPECIFIC INHIBITORS OF TGF-BETA 1 AND USES THEREOF
    Publication number: 20200231682
    Abstract: Disclosed herein are inhibitors, such as antibodies, and antigen binding portions thereof, that selectively bind complexes of LTBP1-TGF?1 and/or LTBP3-TGF?1. The application also provides methods of use of these inhibitors for, for example, inhibiting TGF?1 activation, and treating subjects suffering from TGF?1-related disorders, such as fibrotic conditions. Methods of selecting a context-dependent or context-independent isoform-specific TGF?1 inhibitor for a subject in need thereof are also provided.
    Type: Application
    Filed: July 27, 2018
    Publication date: July 23, 2020
    Inventors: Thomas Schurpf, Christopher Littlefield, Gregory J. Carven, Abhishek Datta
  • TISSUE FACTOR PATHWAY INHIBITOR ANTIBODIES AND USES THEREOF
    Publication number: 20200190214
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Application
    Filed: December 17, 2019
    Publication date: June 18, 2020
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • LRRC33 INHIBITORS AND USE THEREOF
    Publication number: 20200181251
    Abstract: Disclosed herein are LRRC33 inhibiting agents and related methods and uses thereof. More specifically, therapeutic agents for inhibiting LRRC33 effects in vivo are provided. Such agents are useful for the treatment of various disorders involving cells expressing LRRC33 or LRRC33-containing complexes on the surface of cells.
    Type: Application
    Filed: May 9, 2018
    Publication date: June 11, 2020
    Inventors: Alan Buckler, Gregory J. Carven, Stefan Wawersik, Thomas Schurpf, Constance Martin, Abhishek Datta, Mark Allen Farmer
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20200079840
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: March 12, 2020
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson